0001716166
false
0001716166
2023-08-16
2023-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 16, 2023
Vivos
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-39796 |
|
81-3224056 |
(State
or other jurisdiction |
|
(Commission
|
|
(I.R.S.
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
7921
Southpark Plaza, Suite 210
Littleton,
Colorado 80120
(Address
of principal executive offices) (Zip Code)
(866)
908-4867
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
VVOS |
|
The
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Condition.
On
August 16, 2023, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results
for the second quarter ended June 30, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.
The
information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
VIVOS
THERAPEUTICS, INC. |
|
|
Dated:
August 16, 2023 |
By: |
/s/
Bradford Amman |
|
Name: |
Bradford
Amman |
|
Title: |
Chief
Financial Officer |
Exhibit
99.1
Vivos
Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update
Operating
Expenses Decreased 31% Quarter Over Quarter and 25% Year to Date,
Reflecting Cost Cutting Initiatives
Management
to Host Conference Call Today at 6:00 pm ET
LITTLETON,
Colo., August 16, 2023
–
Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technology
company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of
health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities,
today reported financial results and operating highlights for the second quarter and six months ended June 30, 2023.
Second
Quarter 2023 Financial and Operating Summary
|
● |
Revenue
was $3.4 million for the second quarter of 2023 and $7.3 million for the six months ended June 30, 2023, compared to $4.2 million
and $7.8 million for the three and six months ended June 30, 2022, respectively, mainly due to lower product revenue and Vivos Integrated
Provider (“VIP”) enrollments offset by increased revenue from home sleep testing services and seminars conducted at the
Vivos Institute. Importantly, Vivos believes that governmental investigations of third parties with non-FDA approved products in
the sleep apnea treatment space adversely impacted new Vivos case starts and VIP enrollments during the first half of 2023. |
|
|
|
|
● |
Gross
profit was $2.1 million for the second quarter of 2023 and $4.4 million for the six months ended June 30, 2023, compared to $2.6
million and $5.1 million for the comparable periods in 2022, respectively, attributable primarily to the decrease in revenue; |
|
|
|
|
● |
Gross
margin remained the same at 62% for the second quarter of 2023 compared to the prior year period. For the six months ended June 30,
2023 gross margin was 61%, compared 66% for the same period in 2022; |
|
|
|
|
● |
Operating
expenses for the second quarter of 2023 decreased by a significant amount ($2.9 million, or 31%) versus the second quarter of 2022,
reflecting Vivos’ previously announced cost-cutting initiatives including personnel and related expenses. For the six months
ended June 30, 2023 operating expenses decreased by $4.7 million or 25%, compared to the same period in 2022; |
|
|
|
|
● |
The
Company’s cost-cutting initiatives led to significant year-over-year reductions of net loss of $1.5 million or 21% and $5.1
million or 41% for the three and six months ended June 30, 2023, respectively, compared to the same periods in 2022; |
|
|
|
|
● |
Cash
and cash equivalents were $3.9 million at June 30, 2023; |
|
● |
As
of June 30, 2023, patients treated with The Vivos Method totaled approximately 40,000, compared to over 28,000 as of the second quarter
of 2022. Vivos has also trained more than 1,800 dentists in the use of The Vivos Method and Vivos’ related value-added services,
compared to over 1,600 as of the second quarter 2022; |
|
|
|
|
● |
In
May 2023, Vivos announced the results of a clinical observational study on the application of the POD® (being rebranded
as the Vida), in the treatment and prevention of migraine headaches. The study demonstrated statistically significant results, with
ninety-two percent (92%) of study patients reporting their migraine symptoms were completely resolved following completion of treatment.
Migraine headaches affect over 39 million people in the United States alone according to the American Migraine Foundation; and |
|
|
|
|
● |
Overall,
Vivos’ previously stated goal was to decrease costs and increase revenues during 2023 with the aim of becoming cash flow positive
from operations by the first quarter of 2024 without the need for additional financing, if possible. Vivos has successfully implemented
cost savings measures and significantly reduced cash used in operations; however, sales have not grown during 2023 as anticipated
due to external factors and as Vivos continues to refine its product offerings and sales strategies. As such, Vivos now anticipates
that it will likely be required to obtain additional financing to satisfy cash needs as the Company works towards increasing revenue
and achieving cash flow positive operations in the foreseeable future. |
Kirk
Huntsman, Vivos’ Chairman and Chief Executive Officer, stated “Throughout this year we significantly reduced our cash burn,
which led to a 31% second quarter over quarter, and 25% year over year reduction in operating expenses. At the same time, we expanded
our product offerings to address a broader spectrum of patient needs and price points to drive revenue growth. This included our acquisition
of certain key patents, trademarks, product rights and trade secrets earlier in 2023, which filled a gap in our product offerings to
providers and patients. We continue to believe that these developments will allow us to begin to see revenue improvement here in the
second half of 2023.”
Mr.
Huntsman continued, “That said, we believe revenues in our second quarter were adversely impacted by a widely publicized lawsuit
and ensuing governmental, including criminal, investigations into a non-Vivos, non-FDA cleared oral appliance purporting to treat sleep
apnea. Although Vivos was uninvolved in these matters, we believe the negative publicity, rumors and speculation created significant
confusion and concern in the marketplace. Not long after reports of this matter began to circulate, we saw a decline in both new VIP
enrollments and appliance sales, and these declines continued throughout the second quarter. What we know is this: Vivos products are
FDA-approved for their indicated uses, and we believe this creates an opportunity for us to distinguish our products from lesser
competition. So while we’ve faced some headwinds in the market on the revenue side, we also see new opportunities emerging as we
seek to achieve revenue momentum across our entire suite of products.”
“The
second quarter also saw continued progress in our pilot tests with certain Dental Service Organizations (“DSOs”), including
the execution of new and existing pilots during the quarter with eight regional and national DSOs representing over 1,000 locations nationwide.
We also executed our first non-exclusive distribution agreement for a 90-day pilot with a nationally recognized durable medical equipment
company (“DME”) focused on the respiratory space, that serves hundreds of thousands of CPAP patients nationwide who are seeking
alternatives. We hope to provide further public details about this DME collaboration following the conclusion of the 90-day trial, but
so far it appears promising as a means of expanding our sales reach. Our team is very excited about these relationships and we expect
to enter into additional, similar relationships during the remainder of 2023 and beyond” continued Mr. Huntsman.
“Through
the combination of our strategic revenue initiatives, internal operating cost reductions, and new capital raising initiatives, we believe
we have positioned Vivos to achieve revenue growth and, ultimately, cash flow positive operations and profitability in the foreseeable
future. In summary, while the larger economic and market environment is creating challenges for both the medical and dental communities,
Vivos has taken steps to address those challenges and our long-term growth drivers remain in place. With our innovative, evidence-based
technology and network of trained providers, we remain committed to our core mission of addressing the crisis of sleep apnea and breathing
related sleep issues,” Mr. Huntsman concluded.
Vivos
encourages investors and other interested parties to join its conference call today at 6:00 p.m. Eastern time (details below), where
management will discuss further details on topics including: (i) Vivos’ expanded product line and revenue potential, (ii) the potential
significant impact of Vivos’ recent discussions with DME companies on Vivos’ near-term growth, (iii) an update on Vivos’
DSO and DME sales and marketing efforts; (iv) additional programs for dentists to enroll with Vivos, and (v) Vivos’ current cash
position and actions taken to reduce cash burn.
In
addition, further information on Vivos’ financial results is included on the attached unaudited condensed consolidated balance
sheets and statements of operations, and additional explanations of Vivos’ financial performance are provided in the Vivos’
Quarterly Report on Form 10-Q for the three and six months ended June 30, 2023, which will be filed with the Securities and Exchange
Commission (“SEC”). The full 10-Q report will be available on the SEC Filings section of the Investor Relations section of
Vivos’ website at https://vivos.com/investor-relations.
Conference
Call
To
access Vivos’ investor conference call, please dial (877) 451-6152, or for international callers, (201) 389-0879. A replay will
be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The
passcode for the live call and the replay is 13740723. The replay will be available until August 30, 2023.
A
live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online
archive of the webcast will be available on the Company’s website for 30 days following the call.
About
Vivos Therapeutics, Inc.
Vivos
Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and
treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate
obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive,
nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in approximately 40,000 patients
treated worldwide by more than 1,800 trained dentists.
The
Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and associated protocols that
alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens
airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea
Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing
in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection
with using The Vivos Method.
For
more information, visit www.vivos.com.
Cautionary
Note Regarding Forward-Looking Statements
This
press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith
contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described
herein. Words such as “may”, “should”, “expects”, “projects,” “intends”,
“plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”
and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant
known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties
and contingencies, many of which are beyond Vivos’ control. Actual results (including, without limitation, the results of Vivos’
sales, marketing and cost cutting initiatives as described herein) may differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may
be unable to implement revenue, sales and marketing strategies that increase revenues, (ii) risks associated with regulatory scrutiny
of and adverse publicity in the sleep apnea treatment sector; (iii) the risk that Vivos may be unable to secure additional financings
on reasonable terms when needed, if at all and (iv) other risk factors described in Vivos’ filings with the Securities and Exchange
Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except
to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions
to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change
in events, conditions, or circumstances on which any statement is based.
Vivos
Investor Relations Contact:
Julie
Gannon
Investor
Relations Officer
720-442-8113
jgannon@vivoslife.com
-Tables
Follow-
VIVOS
THERAPEUTICS INC.
Unaudited
Condensed Consolidated Balance Sheets
(In
Thousands, Except Per Share Amounts)
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 3,942 | | |
$ | 3,519 | |
Accounts receivable, net of allowance of $251 and $712, respectively | |
| 327 | | |
| 457 | |
Prepaid expenses and other current assets | |
| 1,073 | | |
| 1,448 | |
| |
| | | |
| | |
Total current assets | |
| 5,342 | | |
| 5,424 | |
| |
| | | |
| | |
Long-term assets | |
| | | |
| | |
Goodwill | |
| 2,843 | | |
| 2,843 | |
Property and equipment, net | |
| 3,267 | | |
| 3,082 | |
Operating lease right-of-use asset | |
| 1,544 | | |
| 1,695 | |
Intangible assets, net | |
| 445 | | |
| 302 | |
Deposits and other | |
| 308 | | |
| 374 | |
| |
| | | |
| | |
Total assets | |
$ | 13,749 | | |
$ | 13,720 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable | |
$ | 1,325 | | |
$ | 1,411 | |
Accrued expenses | |
| 1,949 | | |
| 1,912 | |
Warrant liability | |
| 2,200 | | |
| - | |
Current portion of contract liabilities | |
| 2,359 | | |
| 2,926 | |
Current portion of operating lease liability | |
| 447 | | |
| 419 | |
Other current liabilities | |
| 160 | | |
| 145 | |
| |
| | | |
| | |
Total current liabilities | |
| 8,440 | | |
| 6,813 | |
| |
| | | |
| | |
Long-term liabilities | |
| | | |
| | |
Contract liabilities, net of current portion | |
| 264 | | |
| 112 | |
Employee retention credit liability | |
| 1,175 | | |
| - | |
Operating lease liability, net of current portion | |
| 1,764 | | |
| 1,994 | |
| |
| | | |
| | |
Total liabilities | |
| 11,643 | | |
| 8,919 | |
| |
| | | |
| | |
Commitments and contingencies | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | |
Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; no shares issued and outstanding | |
| - | | |
| - | |
Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 29,928,786 shares as of June 30, 2023 and 23,012,119 shares as December 31, 2022 | |
| 3 | | |
| 2 | |
Additional paid-in capital | |
| 88,802 | | |
| 84,267 | |
Accumulated deficit | |
| (86,699 | ) | |
| (79,468 | ) |
Total stockholders’ equity | |
| 2,106 | | |
| 4,801 | |
Total liabilities and stockholders’ equity | |
$ | 13,749 | | |
$ | 13,720 | |
VIVOS
THERAPEUTICS INC.
Unaudited
Condensed Consolidated Statements of Operations
(In
Thousands, Except Per Share Amounts)
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
| | | |
| | | |
| | | |
| | |
Product revenue | |
$ | 1,546 | | |
$ | 2,293 | | |
$ | 3,318 | | |
$ | 4,342 | |
Service revenue | |
| 1,849 | | |
| 1,891 | | |
| 3,935 | | |
| 3,486 | |
Total revenue | |
| 3,395 | | |
| 4,184 | | |
| 7,253 | | |
| 7,828 | |
| |
| | | |
| | | |
| | | |
| | |
Cost of sales (exclusive of depreciation and amortization shown separately below) | |
| 1,297 | | |
| 1,596 | | |
| 2,817 | | |
| 2,689 | |
| |
| | | |
| | | |
| | | |
| | |
Gross profit | |
| 2,098 | | |
| 2,588 | | |
| 4,436 | | |
| 5,139 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | |
General and administrative | |
| 5,877 | | |
| 7,691 | | |
| 12,414 | | |
| 15,497 | |
Sales and marketing | |
| 590 | | |
| 1,699 | | |
| 1,220 | | |
| 2,879 | |
Depreciation and amortization | |
| 148 | | |
| 162 | | |
| 323 | | |
| 324 | |
| |
| | | |
| | | |
| | | |
| | |
Total operating expenses | |
| 6,615 | | |
| 9,552 | | |
| 13,957 | | |
| 18,700 | |
| |
| | | |
| | | |
| | | |
| | |
Operating loss | |
| (4,517 | ) | |
| (6,964 | ) | |
| (9,521 | ) | |
| (13,561 | ) |
| |
| | | |
| | | |
| | | |
| | |
Non-operating income (expense) | |
| | | |
| | | |
| | | |
| | |
Other expense | |
| (225 | ) | |
| (37 | ) | |
| (174 | ) | |
| (116 | ) |
PPP loan forgiveness | |
| - | | |
| - | | |
| - | | |
| 1,287 | |
Excess warrant fair value | |
| - | | |
| - | | |
| (6,453 | ) | |
| - | |
Change in fair value of warrant liability, net of issuance costs of $645 | |
| (867 | ) | |
| - | | |
| 8,761 | | |
| - | |
Other income | |
| 81 | | |
| 9 | | |
| 156 | | |
| 68 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (5,528 | ) | |
$ | (6,992 | ) | |
$ | (7,231 | ) | |
$ | (12,322 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share (basic and diluted) | |
$ | (0.18 | ) | |
$ | (0.33 | ) | |
$ | (0.26 | ) | |
$ | (0.58 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of shares of Common Stock outstanding (basic and diluted) | |
| 29,928,786 | | |
| 21,233,485 | | |
| 28,245,084 | | |
| 21,233,485 | |
v3.23.2
Cover
|
Aug. 16, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 16, 2023
|
Entity File Number |
001-39796
|
Entity Registrant Name |
Vivos
Therapeutics, Inc.
|
Entity Central Index Key |
0001716166
|
Entity Tax Identification Number |
81-3224056
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
7921
Southpark Plaza
|
Entity Address, Address Line Two |
Suite 210
|
Entity Address, City or Town |
Littleton
|
Entity Address, State or Province |
CO
|
Entity Address, Postal Zip Code |
80120
|
City Area Code |
(866)
|
Local Phone Number |
908-4867
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
Trading Symbol |
VVOS
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From Apr 2024 to May 2024
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From May 2023 to May 2024